The footprint of kynurenine pathway in every cancer: a new target for chemotherapy

M Ala - European Journal of Pharmacology, 2021 - Elsevier
Abstract Treatment of cancers has always been a challenge for physicians. Typically,
several groups of anti-cancer medications are needed for effective management of an …

Heterogeneity of platelet derived growth factor pathway gene expression profile defines three distinct subgroups of renal cell carcinomas

AM Ferician, OC Ferician, AD Cumpanas… - Cancer Genomics & …, 2022 - cgp.iiarjournals.org
Background/Aim: We previously described four different vascular patterns (reticular, diffuse,
fasciculate, and trabecular) in renal cell carcinoma (RCC) suggesting an early and …

Новый альтернирующий режим при метастатическом почечно-клеточном раке на примере клинического случая

МС Саяпина, СВ Ширяев, АС Крылов, АД Рыжков… - …, 2016 - cyberleninka.ru
В данной статье на примере клинического случая описан новый альтернирующий
режим, включающий чередование иммунотерапии интерфероном (INF) и таргетной …

[HTML][HTML] It occurs naturally in the seeds and stems of several plants, such as the jicama vine plant, and the roots of several members of Fabaceae. Menu

M Ala - rotenoneinhibitor.com
Treatment of cancers has always been a challenge for physicians. Typically, several groups
of anti-cancer medications are needed for effective management of an invasive and …

A new alternating regimen in metastatic renal cell carcinoma presented through a clinical case

MS Sayapina, SV Shiryaev, AS Krylov… - Cancer …, 2016 - oncourology.abvpress.ru
In the article a new alternating regimen which includes alternation between interferon (INF)
immunotherapy and target therapy (sunitinib) is described through a clinical case. Mentions …